BioCardia (BCDA)
Nasdaq Market Closed
BioCardia, Inc. is a clinical-stage biotechnology company focused on cell-based and cell-derived therapies for serious cardiovascular and pulmonary diseases. Its work is aimed at conditions where existing treatments may not adequately restore function or prevent disease progression, including forms of heart failure, chronic myocardial ischemia and acute lung injury.
The company’s lead programs are built around two bone marrow-derived therapeutic platforms. CardiAMP is an autologous therapy, meaning a patient’s own cells are collected, processed and delivered back to the heart. BioCardia is evaluating this approach for ischemic heart failure with reduced ejection fraction and for refractory angina linked to chronic myocardial ischemia. These indications involve patients with limited options despite drug therapy, device therapy or revascularization procedures.
BioCardia also develops an allogeneic mesenchymal stem cell platform designed as an off-the-shelf treatment. Its CardiALLO program applies this technology to ischemic heart failure, while another program targets acute respiratory distress syndrome, a severe inflammatory lung condition. The allogeneic model is intended to support more standardized manufacturing and availability than patient-specific therapies.
A distinctive part of BioCardia’s strategy is its emphasis on targeted delivery to the heart. The company has developed catheter-based systems intended to place therapeutic cells in precise areas of cardiac tissue. As a clinical-stage business, BioCardia’s value is closely tied to trial progress, regulatory outcomes, financing needs and the broader viability of regenerative medicine in cardiovascular care.
Last updated
- Market Cap
- 10.46M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 9.51M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 320 SOQUEL WAY, SUNNYVALE, CA, 94085
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
BioCardia Announces Reverse Stock Split
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 10.46M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 9.51M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -9.82
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.22
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -0.68
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -7.49M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 729.36%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -454.15%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 0.41
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.41
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.34
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 270.56K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.92
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -2.27M | -2.01M | -1.49M | -2.05M | -2.73M |
| EBITDA | -2.26M | -2.01M | -1.48M | -2.05M | -2.71M |
| Net income | -2.26M | -1.98M | -1.48M | -2.05M | -2.71M |
| Basic EPS | -0.21 | -0.06 | -0.24 | -0.4 | -0.59 |
| Diluted EPS | -0.21 | -0.06 | -0.24 | -0.4 | -0.59 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 1.71M | 3.41M | 6.15M | 2.09M | 2.17M |
| Total liabilities | 2.78M | 2.52M | 3.52M | 3.98M | 3.69M |
| Total equity | -1.07M | 895K | 2.63M | -1.89M | -1.52M |
| Cash & equivalents | 951K | 2.5M | 5.29M | 980K | 949K |
| Current assets | 1.14M | 2.73M | 5.37M | 1.2M | 1.17M |
| Current liabilities | 2.78M | 2.43M | 3.31M | 3.64M | 3.23M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -1.66M | -2.5M | -1.67M | -1.65M | -1.62M |
| Investing cash flow | -3K | -6K | 0 | -1K | — |
| Financing cash flow | 117K | -288K | 5.98M | 1.68M | 196K |
| Change in cash | -1.55M | -2.79M | 4.31M | 31K | -1.42M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 10-Q — BioCardia, Inc. | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 10-K — BioCardia, Inc. | View Filing | |
| edgar index | S-8 — BioCardia, Inc. | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | S-8 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 8-K — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Altman Peter | View Filing | |
| edgar index | 3 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| edgar index | 4 — BioCardia, Inc. | View Filing | |
| form 4 | Form 4 — Slosman Marvin | View Filing | |
| form 4 | Form 4 — Blank Andrew Scott | View Filing | |
| form 4 | Form 4 — STERTZER SIMON H | View Filing | |
| form 4 | Form 4 — Facteau Bill | View Filing | |
| form 4 | Form 4 — MOYES JAY M | View Filing | |
| form 4 | Form 4 — Allen Jim L. | View Filing | |
| form 4 | Form 4 — GILLIS EDWARD M | View Filing | |
| form 4 | Form 4 — GILLIS EDWARD M | View Filing | |
| form 4 | Form 4 — GILLIS EDWARD M | View Filing | |
| form 4 | Form 4 — McClung David | View Filing | |
| form 4 | Form 4 — McClung David | View Filing | |
| form 4 | Form 4 — McClung David | View Filing |